B Braun Company Profile

What is the competitive landscape for B BRAUN

B BRAUN has one hundred and twenty-two approved drugs.

There are three US patents protecting B BRAUN drugs.

There are fifty patent family members on B BRAUN drugs in twenty-nine countries and two hundred and fifty-nine supplementary protection certificates in seventeen countries.

Summary for B Braun

International Patents:	50
US Patents:	3
Tradenames:	230
Ingredients:	68
NDAs:	122

Drugs and US Patents for B Braun

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun Medical	MAGNESIUM SULFATE	magnesium sulfate	INJECTABLE;INJECTION	207967-003	Apr 26, 2021	AP	RX	No	No
B Braun	ACETIC ACID 0.25% IN PLASTIC CONTAINER	acetic acid, glacial	SOLUTION;IRRIGATION, URETHRAL	018161-001	Approved Prior to Jan 1, 1982	AT	RX	No	No
B Braun	DEXTROSE 2.5% IN PLASTIC CONTAINER	dextrose	INJECTABLE;INJECTION	019626-001	Feb 2, 1988		DISCN	No	No
B Braun	PHYSIOLYTE IN PLASTIC CONTAINER	magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium gluconate	SOLUTION;IRRIGATION	019024-001	Jun 8, 1984		RX	No	No
B Braun	LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER	lidocaine hydrochloride	INJECTABLE;INJECTION	019830-004	Apr 8, 1992	AP	RX	No	No
B Braun	THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019083-003	Nov 7, 1984		DISCN	No	No

Expired US Patents for B Braun

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
B Braun	HEPATAMINE 8%	amino acids	INJECTABLE;INJECTION	018676-001	Aug 3, 1982	3,950,529
B Braun	UCEPHAN	sodium benzoate; sodium phenylacetate	SOLUTION;ORAL	019530-001	Dec 23, 1987	4,284,647

International Patents for B Braun Drugs

Country	Patent Number	Estimated Expiration
Slovenia	1931304
Mexico	356212
Philippines	12015501313
Australia	2013356855
Japan	6347784
Italy	MI20051633

Supplementary Protection Certificates for B Braun Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	CR 2014 00050	Denmark		PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
2404919	CR 2016 00019	Denmark		PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCATBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOSYRE, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ELLER ET ESTERPRODRUG DERAF; REG. NO/DATE: EU/1/15/1059 20151124
3412676	202040020	Slovenia		PRODUCT NAME: COMBINATION OF VABORBACTAM AND/OR ITS SALT AND/OR ITS HYDRATE AND MEROPENEM AND/OR ITS SALT AND/OR ITS HYDRATE, MAINLY MEROPENEM TRIHYDRATE; NATIONAL AUTHORISATION NUMBER: EU/1/18/1334/001; DATE OF NATIONAL AUTHORISATION: 20181120; AUTHORITY FOR NATIONAL AUTHORISATION: EU
0268956	1999C0030	Belgium		PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
1874117	2014/032	Ireland		PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
1586316	SPC/GB11/054	United Kingdom		PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• B Braun
• B Braun Medical

Pharmaceutical Competitive Landscape Analysis: B. Braun – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

What is B. Braun's Position in the Pharmaceutical Industry?

B. Braun operates primarily in healthcare products and services, with a focus on infusion therapies, critical care, and surgical instruments. It maintains a strong presence in hospital settings across North America, Europe, and Asia. Although not a conventional pharmaceutical company, it develops and supplies active pharmaceutical ingredients (APIs), particularly in anesthesia, pain management, and specialty therapies.

Market Share and Revenue (2022):

• Total revenue: €8.1 billion
• Pharmaceuticals segment accounts for approximately 12% (€972 million) of total revenue
• Operates in over 60 countries with a presence in hospital care, outpatient clinics, and home care

Competitive Position:
B. Braun ranks among the top 10 medical device companies globally. Its pharmaceutical activities are more niche, focusing on high-margin hospital pharmaceutical products rather than broad-based drug manufacturing. The company's diversified portfolio reduces dependency on any single product category.

How Does B. Braun Compare with Major Competitors?

Company	Revenue (2022)	Core Focus	Market Reach	Notable Strengths
B. Braun	€8.1 billion	Hospital supplies, infusion therapy, select APIs	Global, especially Europe and North America	Integrated manufacturing, extensive hospital networks
Fresenius Kabi	€7.3 billion	IV drugs, infusion therapy, biosimilars	Over 100 countries	Broad pharmaceutical portfolio, strong presence in APIs
BD (Becton Dickinson)	€19.9 billion	Medical devices, pharmaceuticals	Worldwide	Innovative drug delivery devices, sterile solutions
Baxter Healthcare	€14.2 billion	IV therapies, renal, and surgical products	Over 100 countries	Diversified healthcare solutions

B. Braun’s revenues and market share trail behind major pharmaceutical-focused firms like Fresenius Kabi and Baxter but compete effectively within hospital-centric segments.

What are B. Braun's Core Strengths?

Integrated Supply Chain

The company owns manufacturing facilities across continents, enabling control over quality and supply. This allows for rapid response to hospital needs and enhances reliability.

Focused Product Portfolio

B. Braun concentrates on infusion systems, surgical instruments, and specific hospital pharmaceuticals. Its expertise lies in high-margin products deployed in critical care, enabling sustained profitability.

Geographic Diversification

Presence in North America, Europe, and Asia provides regional stability and access to emerging markets. The company adapts its product offerings for local regulatory and clinical practices.

R&D Capabilities

Invests approximately €200 million annually in research and development. Key focus areas include needle safety, smart infusion systems, and novel pharmaceuticals for perioperative care.

Strategic Partnerships

Collaborations with biotech firms enable B. Braun to expand its pharmaceutical offerings. Notably, its partnership with BioNTech in vaccine delivery systems exemplifies such strategic moves.

What are the Strategic Opportunities for B. Braun?

Expansion in Biosimilars and Specialty Drugs

Growing demand for biosimilars and personalized therapies offers growth pathways in hospital and outpatient markets. B. Braun can leverage existing distribution channels to introduce generic biologics.

Digital and Smart Infusion Devices

Developing connected infusion systems can reduce medication errors and improve patient safety. B. Braun’s R&D investments support this transition.

Market Penetration in Emerging Economies

Expanding manufacturing and sales in Asia-Pacific and Latin America can capitalize on rising hospital infrastructure development and healthcare spending.

Strategic Acquisitions and Collaborations

Targeted acquisitions of innovative biotech firms can augment B. Braun’s portfolio of specialty pharmaceuticals and APIs.

Complying with Regulatory Changes

Proactive adaptation to evolving regulatory standards in the US (FDA), EU (EMA), and emerging markets ensures uninterrupted product access and competitive advantage.

What are the Challenges Facing B. Braun?

• Limited presence in broad-spectrum pharmaceuticals compared to top pharma firms.
• Regulatory complexity in diverse markets restricts rapid product launches.
• The hospital-centric business model faces pressures from outpatient and home care shifts.
• Competition from large pharma firms entering hospital supply segments with integrated pharmaceutical and device solutions.

Key Takeaways

• B. Braun maintains a prominent position within hospital-focused healthcare segments, demonstrating strengths in integrated manufacturing, geographic reach, and product specialization.
• It operates a niche pharmaceutical segment with growth potential in biosimilars, specialty therapies, and digital health.
• Strategic expansion into emerging markets and collaborations with biotech firms can mitigate growth limitations.
• Competition from diversified pharma companies and shifts toward outpatient care remain significant external pressures.

FAQs

1. What percentage of B. Braun’s revenue comes from pharmaceuticals?
Approximately 12% (€972 million of €8.1 billion total).

2. Which regions are B. Braun’s primary markets?
Europe, North America, and Asia.

3. Is B. Braun involved in biosimilar development?
Not extensively but explores biosimilars and specialty therapies through strategic collaborations.

4. How does B. Braun differentiate its product offerings?
Through integrated manufacturing, focus on hospital infusion and surgical products, and digital health solutions.

5. What growth opportunities exist for B. Braun in the next five years?
Expansion in biosimilars, digital infusion systems, and emerging markets; acquisitions of biotech firms; alignments with regulatory trends.

References

1. B. Braun Group. (2022). Annual Report 2022. Retrieved from https://www.bbraun.com
2. MarketsandMarkets. (2023). Infusion Therapy Devices Market.
3. Statista. (2023). Top Medical Device Companies Worldwide [Data set].
4. Forth, K. (2022). Strategic Review of Hospital Pharmaceutical Industry. Journal of Healthcare Business.